Back

EASL-ILC-I 2020 - International Liver Congress of the European Association for the Study of the Liver (Virtual Meeting)

Aug 27 - Aug 29, 2020 | LondonUK

LARVOL is not affiliated with International Liver Congress of the European Association for the Study of the Liver (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Condition
Stage
Treatment
Setting
Biomarker
Trial Name/ID

Showing 70 abstracts linked to Trials

[VIRTUAL] A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma

[VIRTUAL] Atezolizumab + bevacizumab vs. sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study

[VIRTUAL] Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells

[VIRTUAL] Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

[VIRTUAL] Updated data from an ongoing study with ADP-A2AFP spear T-cells

[VIRTUAL] Quantitative magnetic resonance imaging predicts individual future liver performance after liver reception for cancer

  • Poster

[VIRTUAL] A phase 1/2 open label extension study of givosiran, an investigational RNAi therapeutic, in patients with acute intermittent porphyria

  • Poster

[VIRTUAL] Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the ENVISION open label extension

[VIRTUAL] RO7062931 anti-sense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy

[VIRTUAL] Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1)

[VIRTUAL] Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomised phase 2b study

[VIRTUAL] EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a ARGON-1 study

[VIRTUAL] Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

  • Late-Breaking, Oral

[VIRTUAL] The effect of chyme reinfusion on the bile salt/fibroblast growth factor 19 signalling axis in intestinal failure patients with a temporary jejunal double enterostomy

[VIRTUAL] Prophylaxis with norfloxacin is not associated with multidrug resistant bacterial infections